Aroa Biosurgery (ASX:ARX) Retained Earnings: A$-44.87 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ARX Aroa Biosurgery Ltd ASX:ARX
60 GF Score
Price A$0.59
GF Value A$0.81
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Aroa Biosurgery Retained Earnings?

Aroa Biosurgery ASX:ARX -2.50% 60 Retained Earnings is A$-44.87 Mil as of Mar. 2026. GuruFocus rates ASX:ARX with a GF Score™ of 60/100 and a GF Value™ of A$0.81 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Aroa Biosurgery's retained earnings for the quarter that ended in Mar. 2026 was A$-44.87 Mil.

Aroa Biosurgery's quarterly retained earnings increased from Mar. 2025 (A$-58.21 Mil) to Sep. 2025 (A$-57.28 Mil) and increased from Sep. 2025 (A$-57.28 Mil) to Mar. 2026 (A$-44.87 Mil).

Aroa Biosurgery's annual retained earnings declined from Mar. 2024 (A$-57.02 Mil) to Mar. 2025 (A$-58.21 Mil) but then increased from Mar. 2025 (A$-58.21 Mil) to Mar. 2026 (A$-44.87 Mil).


Aroa Biosurgery  (ASX:ARX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Aroa Biosurgery Retained Earnings Historical Data

* Premium members only.

The historical data trend for Aroa Biosurgery's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery Retained Earnings Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Retained Earnings
Get a 7-Day Free Trial -47.52 -48.23 -57.02 -58.21 -44.87

Aroa Biosurgery Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -57.02 -59.05 -58.21 -57.28 -44.87
ASX:ARX
60GF Score
Aroa Biosurgery Ltd ASX:ARX
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aroa Biosurgery Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of A$-44.87 Mil mean?
Aroa Biosurgery (ASX:ARX) has a Retained Earnings of A$-44.87 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Aroa Biosurgery and its competitors.
Is Aroa Biosurgery's Retained Earnings too high?
Aroa Biosurgery's current Retained Earnings is A$-44.87 Mil. Overall, Aroa Biosurgery has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Retained Earnings compare to ABT and SYK?
Aroa Biosurgery's Retained Earnings of A$-44.87 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Aroa Biosurgery and its competitors. Aroa Biosurgery's current Retained Earnings is A$-44.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.81, compared to a current price of A$0.59 — trading 27.8% below its estimated fair value. The current Retained Earnings is A$-44.87 Mil. Aroa Biosurgery's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Retained Earnings is A$-44.87 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?

Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued. The current stock price of A$0.59 is trading 27.8% below its estimated GF Value™ of A$0.81. GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.

Key valuation signals for ASX:ARX:

  • Retained Earnings: A$-44.87 Mil
  • GF Value™: A$0.81 vs. price of A$0.59 (27.8% below fair value)
  • GF Score™: 60/100 with 1 warning sign

No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aroa Biosurgery Business Description

Other Exchanges AROAF:USA
Address 64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
60GF Score

Get the complete analysis for ASX:ARX

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.59
Price
A$0.81
GF Value